Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats.

Tomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, Read LC, Ballard FJ

The Biochemical journal1 Feb 1992Cited by 63 (Europe PMC)

PMID1371669PMCIDPMC1130894DOI10.1042/bj2820091PepBankPUB-01371669

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

1 result from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In dexamethasone-treated rats, LR3IGF-I was approximately 2.5-fold more potent than IGF-I.
In plain wordsIn rats given dexamethasone, LR3IGF-I was about 2.5 times more potent than regular IGF-I.
Peptide
IGF-1 LR3
Outcome
IncreaseAnabolic potency relative to IGF-I (body weight and nitrogen retention)
Study
ratn: not reported in source
150 g male rats made catabolic with dexamethasone
Comparator
IGF-I
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous osmotic pump · 7 daysAs given in this study (rat).
Measurements
Relative potency vs IGF-I
≈ 2.5 fold
LR3IGF-I
Source sentences
Summary
Two IGF-I analogues that bind poorly to IGF-binding proteins, the truncated form, des(1-3)IGF-I, and a variant with an N-terminal extension as well as arginine at residue 3, LR3IGF-I, were approx. 2.5-fold more potent than IGF-I.
2 context sentences(design, population, supporting numbers)
Summary · context
Marked dose-dependent effects on body weight and nitrogen retention
Summary · context
The administration of insulin-like growth factor-I (IGF-I) via subcutaneously implanted osmotic pumps partially reversed a catabolic state produced by the co-administration of 20 micrograms of dexamethasone/day to 150 g male rats.
Report a problemFND-0137166901

Studies that did not test the peptide alone13

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

02AnimalNot a test of IGF-1 LR3 aloneAnimal study (in vivo)Mechanism
In rats, treatment with IGF-I or its variants, including LR3IGF-I, in dexamethasone-treated animals substantially increased plasma levels of IGF-binding proteins, particularly IGFBP-3.
In plain wordsIn rats, IGF-I or its variants raised blood levels of IGF-binding proteins, particularly IGFBP-3.
Peptide
IGF-1 LR3
Outcome
IncreasePlasma IGF-binding protein levels (IGFBP-3)
Study
ratn: not reported in source
150 g male rats made catabolic with dexamethasone
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
substantially increased plasma levels of IGF-binding proteins, particularly IGFBP-3, produced by the combined treatment of dexamethasone with IGF-I or the variants
1 context sentence(design, population, supporting numbers)
Summary · context
The administration of insulin-like growth factor-I (IGF-I) via subcutaneously implanted osmotic pumps partially reversed a catabolic state produced by the co-administration of 20 micrograms of dexamethasone/day to 150 g male rats.
In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.
Report a problemFND-0137166902
03AnimalNot a test of IGF-1 LR3 aloneAnimal study (in vivo)Efficacy outcome
In dexamethasone-treated rats, the IGF peptides (IGF-I and its analogues) had anabolic effects on muscle protein synthesis.
In plain wordsIn rats given dexamethasone, IGF peptides together increased muscle protein synthesis.
Peptide
IGF-1 LR3
Outcome
IncreaseMuscle protein synthesis
Study
ratn: not reported in source
150 g male rats made catabolic with dexamethasone
Outcome group
Body weight · Musculoskeletal
Source sentences
Summary
Measurements of muscle protein synthesis at the end of the treatment period and muscle protein breakdown by 3-methylhistidine (3MH) excretion throughout the experiment indicated coordinate anabolic effects of the IGF peptides on both processes.
1 context sentence(design, population, supporting numbers)
Summary · context
The administration of insulin-like growth factor-I (IGF-I) via subcutaneously implanted osmotic pumps partially reversed a catabolic state produced by the co-administration of 20 micrograms of dexamethasone/day to 150 g male rats.
In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.
Report a problemFND-0137166903
04AnimalNot a test of IGF-1 LR3 aloneAnimal study (in vivo)Efficacy outcome
In dexamethasone-treated rats, the IGF peptides (IGF-I and its analogues) had anabolic effects on muscle protein breakdown.
In plain wordsIn rats given dexamethasone, IGF peptides together reduced muscle protein breakdown.
Peptide
IGF-1 LR3
Outcome
DecreaseMuscle protein breakdown (3-methylhistidine excretion)
Study
ratn: not reported in source
150 g male rats made catabolic with dexamethasone
Outcome group
Body weight · Musculoskeletal
Source sentences
Summary
Measurements of muscle protein synthesis at the end of the treatment period and muscle protein breakdown by 3-methylhistidine (3MH) excretion throughout the experiment indicated coordinate anabolic effects of the IGF peptides on both processes.
1 context sentence(design, population, supporting numbers)
Summary · context
The administration of insulin-like growth factor-I (IGF-I) via subcutaneously implanted osmotic pumps partially reversed a catabolic state produced by the co-administration of 20 micrograms of dexamethasone/day to 150 g male rats.
In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.
Report a problemFND-0137166904
05AnimalNot a test of IGF-1 LR3 aloneAnimal study (in vivo)Efficacy outcome
In dexamethasone-treated rats, IGF-I and especially the IGF analogues increased gut weight by up to 45%.
In plain wordsIn rats given dexamethasone, IGF-I and especially its analogues increased gut weight.
Peptide
IGF-1 LR3
Outcome
IncreaseGut weight
Study
ratn: not reported in source
150 g male rats made catabolic with dexamethasone
Outcome group
Intestinal growth and absorption · Gastrointestinal
Source sentences
Summary
IGF-I and especially the IGF analogues increased the gut weight by up to 45%.
1 context sentence(design, population, supporting numbers)
Summary · context
The administration of insulin-like growth factor-I (IGF-I) via subcutaneously implanted osmotic pumps partially reversed a catabolic state produced by the co-administration of 20 micrograms of dexamethasone/day to 150 g male rats.
In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.
Report a problemFND-0137166905
06AnimalNot a test of IGF-1 LR3 aloneAnimal study (in vivo)Efficacy outcome
In dexamethasone-treated rats, the increase in total carcass weight with IGF treatment reflected nitrogen rather than fat gain.
In plain wordsIn rats given dexamethasone, IGF treatment raised carcass weight through nitrogen gain, not fat gain.
Peptide
IGF-1 LR3
Outcome
IncreaseCarcass composition
Study
ratn: not reported in source
150 g male rats made catabolic with dexamethasone
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
the increase in total carcass weight reflected nitrogen rather than fat gain.
1 context sentence(design, population, supporting numbers)
Summary · context
The administration of insulin-like growth factor-I (IGF-I) via subcutaneously implanted osmotic pumps partially reversed a catabolic state produced by the co-administration of 20 micrograms of dexamethasone/day to 150 g male rats.
In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.
Report a problemFND-0137166906
07AnimalNot a test of IGF-1 LR3 aloneAnimal study (in vivo)Efficacy outcome
In dexamethasone-treated rats, IGF treatment restored the dexamethasone-induced changes in liver, spleen and heart weight towards normal.
In plain wordsIn rats given dexamethasone, IGF treatment moved liver, spleen and heart weights back toward normal.
Peptide
IGF-1 LR3
Outcome
MixedLiver, spleen and heart weight
Study
ratn: not reported in source
150 g male rats made catabolic with dexamethasone
Outcome group
Body weight · Whole body
Source sentences
Summary
The dexamethasone-induced changes in liver, spleen and heart weight were restored towards normal by the IGF treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
The administration of insulin-like growth factor-I (IGF-I) via subcutaneously implanted osmotic pumps partially reversed a catabolic state produced by the co-administration of 20 micrograms of dexamethasone/day to 150 g male rats.
In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.
Report a problemFND-0137166907
08AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Efficacy outcome
In dexamethasone-treated rats, the two IGF-I analogues including des(1‑3)IGF-I were approximately 2.5-fold more potent than IGF-I.
In plain wordsIn rats treated with dexamethasone, the two analogues including des(1‑3)IGF-I had greater anabolic potency than IGF-I.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
IncreaseAnabolic potency of the two variants
Study
ratn: not reported in source
dexamethasone-treated male rats
Comparator
IGF-I
Outcome group
Growth hormone and IGF-1 · Metabolic and weight
Measurements
Relative anabolic potency
≈ 2.5 fold
two analogues versus IGF-I
Source sentences
Summary
Two IGF-I analogues that bind poorly to IGF-binding proteins, the truncated form, des(1-3)IGF-I, and a variant with an N-terminal extension as well as arginine at residue 3, LR3IGF-I, were approx. 2.5-fold more potent than IGF-I.
1 context sentence(design, population, supporting numbers)
Summary · context
The administration of insulin-like growth factor-I (IGF-I) via subcutaneously implanted osmotic pumps partially reversed a catabolic state produced by the co-administration of 20 micrograms of dexamethasone/day to 150 g male rats.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-0137166908
09AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Efficacy outcome
In dexamethasone-treated rats, pooled IGF-I or variant treatment increased plasma IGF-binding proteins, particularly IGFBP-3.
In plain wordsIn rats treated with dexamethasone, pooled IGF-I or variant treatment increased natural IGF-binding proteins, especially IGFBP-3.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
IncreasePlasma IGF-binding proteins
Study
ratn: not reported in source
dexamethasone-treated male rats
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
The increased potencies of the IGF-I variants may relate to the substantially increased plasma levels of IGF-binding proteins, particularly IGFBP-3, produced by the combined treatment of dexamethasone with IGF-I or the variants.
2 context sentences(design, population, supporting numbers)
Summary · context
The administration of insulin-like growth factor-I (IGF-I) via subcutaneously implanted osmotic pumps partially reversed a catabolic state produced by the co-administration of 20 micrograms of dexamethasone/day to 150 g male rats.
Summary · context
Two IGF-I analogues that bind poorly to IGF-binding proteins, the truncated form, des(1-3)IGF-I, and a variant with an N-terminal extension as well as arginine at residue 3, LR3IGF-I, were approx. 2.5-fold more potent than IGF-I.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-0137166909
10AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Efficacy outcome
In dexamethasone-treated rats, pooled IGF peptide treatment showed anabolic effects on muscle protein synthesis.
In plain wordsIn rats treated with dexamethasone, pooled IGF peptide treatment increased muscle protein synthesis.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
IncreaseMuscle protein synthesis
Study
ratn: not reported in source
dexamethasone-treated male rats
Outcome group
Muscle injury and repair · Metabolic and weight
Source sentences
Summary
Measurements of muscle protein synthesis at the end of the treatment period and muscle protein breakdown by 3-methylhistidine (3MH) excretion throughout the experiment indicated coordinate anabolic effects of the IGF peptides on both processes.
2 context sentences(design, population, supporting numbers)
Summary · context
The administration of insulin-like growth factor-I (IGF-I) via subcutaneously implanted osmotic pumps partially reversed a catabolic state produced by the co-administration of 20 micrograms of dexamethasone/day to 150 g male rats.
Summary · context
Two IGF-I analogues that bind poorly to IGF-binding proteins, the truncated form, des(1-3)IGF-I, and a variant with an N-terminal extension as well as arginine at residue 3, LR3IGF-I, were approx. 2.5-fold more potent than IGF-I.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-0137166910
11AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Efficacy outcome
In dexamethasone-treated rats, pooled IGF peptide treatment showed anabolic effects on muscle protein breakdown measured by 3-methylhistidine excretion.
In plain wordsIn rats treated with dexamethasone, pooled IGF peptide treatment reduced muscle protein breakdown.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
DecreaseMuscle protein breakdown
Study
ratn: not reported in source
dexamethasone-treated male rats
Outcome group
Muscle injury and repair · Metabolic and weight
Source sentences
Summary
Measurements of muscle protein synthesis at the end of the treatment period and muscle protein breakdown by 3-methylhistidine (3MH) excretion throughout the experiment indicated coordinate anabolic effects of the IGF peptides on both processes.
2 context sentences(design, population, supporting numbers)
Summary · context
The administration of insulin-like growth factor-I (IGF-I) via subcutaneously implanted osmotic pumps partially reversed a catabolic state produced by the co-administration of 20 micrograms of dexamethasone/day to 150 g male rats.
Summary · context
Two IGF-I analogues that bind poorly to IGF-binding proteins, the truncated form, des(1-3)IGF-I, and a variant with an N-terminal extension as well as arginine at residue 3, LR3IGF-I, were approx. 2.5-fold more potent than IGF-I.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-0137166911
12AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Efficacy outcome
In dexamethasone-treated rats, pooled IGF-I and analogue treatment increased gut weight by up to 45%.
In plain wordsIn rats treated with dexamethasone, pooled IGF-I and analogue treatment increased gut weight.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
IncreaseGut weight
Study
ratn: not reported in source
dexamethasone-treated male rats
Outcome group
Gastrointestinal protection · Gastrointestinal
Measurements
Gut weight increase
≤ 45%
IGF-I and IGF analogues
Source sentences
Summary
Part of this response in 3MH excretion may have reflected a decrease in gut protein breakdown, because IGF-I and especially the IGF analogues increased the gut weight by up to 45%.
2 context sentences(design, population, supporting numbers)
Summary · context
The administration of insulin-like growth factor-I (IGF-I) via subcutaneously implanted osmotic pumps partially reversed a catabolic state produced by the co-administration of 20 micrograms of dexamethasone/day to 150 g male rats.
Summary · context
Two IGF-I analogues that bind poorly to IGF-binding proteins, the truncated form, des(1-3)IGF-I, and a variant with an N-terminal extension as well as arginine at residue 3, LR3IGF-I, were approx. 2.5-fold more potent than IGF-I.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-0137166912
13AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Efficacy outcome
In dexamethasone-treated rats, fractional carcass weights remained low in pooled IGF-treated groups.
In plain wordsIn rats treated with dexamethasone, fractional carcass weights remained low across pooled IGF treatments.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
Direction not reportedFractional carcass weight
Study
ratn: not reported in source
dexamethasone-treated male rats
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Notwithstanding the effects on protein synthesis and breakdown, the fractional carcass weights remained low in the IGF-treated groups, although the increase in total carcass weight reflected nitrogen rather than fat gain.
2 context sentences(design, population, supporting numbers)
Summary · context
The administration of insulin-like growth factor-I (IGF-I) via subcutaneously implanted osmotic pumps partially reversed a catabolic state produced by the co-administration of 20 micrograms of dexamethasone/day to 150 g male rats.
Summary · context
Two IGF-I analogues that bind poorly to IGF-binding proteins, the truncated form, des(1-3)IGF-I, and a variant with an N-terminal extension as well as arginine at residue 3, LR3IGF-I, were approx. 2.5-fold more potent than IGF-I.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-0137166913
14AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Efficacy outcome
In dexamethasone-treated rats, pooled IGF treatment increased total carcass weight through nitrogen rather than fat gain.
In plain wordsIn rats treated with dexamethasone, pooled IGF treatment increased carcass weight through nitrogen gain.
Peptide
IGF-1 DES (des(1-3)IGF-I)
Outcome
IncreaseTotal carcass weight
Study
ratn: not reported in source
dexamethasone-treated male rats
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Notwithstanding the effects on protein synthesis and breakdown, the fractional carcass weights remained low in the IGF-treated groups, although the increase in total carcass weight reflected nitrogen rather than fat gain.
2 context sentences(design, population, supporting numbers)
Summary · context
The administration of insulin-like growth factor-I (IGF-I) via subcutaneously implanted osmotic pumps partially reversed a catabolic state produced by the co-administration of 20 micrograms of dexamethasone/day to 150 g male rats.
Summary · context
Two IGF-I analogues that bind poorly to IGF-binding proteins, the truncated form, des(1-3)IGF-I, and a variant with an N-terminal extension as well as arginine at residue 3, LR3IGF-I, were approx. 2.5-fold more potent than IGF-I.
In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).
Report a problemFND-0137166914

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 4Current
21 Oct 2026, 13:52 UTC
The same notice was added 2 times, first on 21 Oct 2026, 12:50 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 2
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.